Further studies should explore how the interaction between AE and the full‐length FOXC2 influences the overall function of FOXC2 in fibrotic processes, and whether targeting the Ser125 residue could serve as a novel therapeutic strategy for PPA. The gene discussed is FOXC2; the disease is primary progressive aphasia.